Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Protein Arginine Methyltransferase 5 (PRMT5) Promotes Survival of Lymphoma Cells via Activation of WNT/β-CATENIN and AKT/GSK3β Proliferative Signaling.

Chung J, Karkhanis V, Baiocchi RA, Sif S.

J Biol Chem. 2019 Mar 18. pii: jbc.RA119.007640. doi: 10.1074/jbc.RA119.007640. [Epub ahead of print]

2.

Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Harrington BK, Wheeler E, Hornbuckle K, Y Shana'ah A, Youssef Y, Smith L, Hassan Ii Q, Klamer B, Zhang X, Long M, Baiocchi RA, Maddocks K, Johnson AJ, Byrd JC, Alinari L.

Leuk Lymphoma. 2019 Mar 1:1-10. doi: 10.1080/10428194.2019.1569231. [Epub ahead of print]

PMID:
30821551
3.

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.

Bond DA, Dotson E, Awan FT, Baiocchi RA, Blum KA, Maddocks K.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):e123-e128. doi: 10.1016/j.clml.2018.11.020. Epub 2018 Nov 29. No abstract available.

PMID:
30594446
4.

PU.1 and epigenetic signals modulate 1,25-dihydroxyvitamin D3 and C/EBPα regulation of the human cathelicidin antimicrobial peptide gene in lung epithelial cells.

Wei R, Dhawan P, Baiocchi RA, Kim KY, Christakos S.

J Cell Physiol. 2019 Jul;234(7):10345-10359. doi: 10.1002/jcp.27702. Epub 2018 Nov 1.

PMID:
30387140
5.

Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy.

Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA.

Expert Opin Ther Targets. 2018 Jun;22(6):527-545. doi: 10.1080/14728222.2018.1474203. Epub 2018 May 21. Review.

PMID:
29781349
6.

Oral Mycosis Fungoides: A Report of Three Cases and Review of the Literature.

Rosebush MS, Allen CM, Accurso BT, Baiocchi RA, Cordell KG.

Head Neck Pathol. 2018 Apr 26. doi: 10.1007/s12105-018-0923-5. [Epub ahead of print]

PMID:
29700722
7.

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.

Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA.

Clin Cancer Res. 2018 Jul 15;24(14):3273-3281. doi: 10.1158/1078-0432.CCR-17-2685. Epub 2018 Apr 9.

8.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R.

Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 Jan 31.

PMID:
29386193
9.

Correction: PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Webb LM, Amici SA, Jablonski KA, Savardekar H, Panfil AR, Li L, Zhou W, Peine K, Karkhanis V, Bachelder EM, Ainslie KM, Green PL, Li C, Baiocchi RA, Guerau-de-Arellano M.

J Immunol. 2017 Oct 15;199(8):3004. doi: 10.4049/jimmunol.1701237. No abstract available.

10.

Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Haverkos BM, Coleman C, Gru AA, Pan Z, Brammer J, Rochford R, Mishra A, Oakes CC, Baiocchi RA, Freud AG, Porcu P.

Discov Med. 2017 Mar;23(126):189-199. Review.

11.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC.

Leuk Lymphoma. 2017 Oct;58(10):2310-2318. doi: 10.1080/10428194.2017.1298751. Epub 2017 Mar 7.

12.

Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.

Kumar B, Yadav A, Brown NV, Zhao S, Cipolla MJ, Wakely PE, Schmitt AC, Baiocchi RA, Teknos TN, Old M, Kumar P.

Oncotarget. 2017 Feb 28;8(9):14847-14859. doi: 10.18632/oncotarget.14682.

13.

PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Webb LM, Amici SA, Jablonski KA, Savardekar H, Panfil AR, Li L, Zhou W, Peine K, Karkhanis V, Bachelder EM, Ainslie KM, Green PL, Li C, Baiocchi RA, Guerau-de-Arellano M.

J Immunol. 2017 Feb 15;198(4):1439-1451. doi: 10.4049/jimmunol.1601702. Epub 2017 Jan 13. Erratum in: J Immunol. 2017 Oct 15;199(8):3004.

14.

Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.

Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P.

Int J Cancer. 2017 Apr 15;140(8):1899-1906. doi: 10.1002/ijc.30566.

15.

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P.

Curr Hematol Malig Rep. 2016 Dec;11(6):514-527. doi: 10.1007/s11899-016-0355-9. Review.

16.

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.

Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S181-S190.e4. doi: 10.1016/j.clml.2016.02.014.

17.

NKp80 Defines a Critical Step during Human Natural Killer Cell Development.

Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE 3rd, Caligiuri MA.

Cell Rep. 2016 Jul 12;16(2):379-391. doi: 10.1016/j.celrep.2016.05.095. Epub 2016 Jun 30.

18.

Murine Models of Epstein-Barr Virus-Associated Lymphomagenesis.

Ahmed EH, Baiocchi RA.

ILAR J. 2016;57(1):55-62. doi: 10.1093/ilar/ilv074.

19.

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells.

Mates JM, de Silva S, Lustberg M, Van Deusen K, Baiocchi RA, Wu L, Kwiek JJ.

Retrovirology (Auckl). 2015;7:1-5. Epub 2015 Oct 15.

20.

PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival.

Panfil AR, Al-Saleem J, Howard CM, Mates JM, Kwiek JJ, Baiocchi RA, Green PL.

Viruses. 2015 Dec 30;8(1). pii: E7. doi: 10.3390/v8010007.

21.

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.

Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci G.

Leukemia. 2016 Apr;30(4):789-99. doi: 10.1038/leu.2015.308. Epub 2015 Nov 5.

PMID:
26536822
22.

The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Gru AA, Haverkos BH, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, Vigil CE, Rochford R, Natkunam Y, Baiocchi RA, Porcu P.

Curr Hematol Malig Rep. 2015 Dec;10(4):456-67. doi: 10.1007/s11899-015-0292-z. Review.

23.

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA.

Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7.

PMID:
25847298
24.

Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung JH, Smith EM, Quinion C, Smith PL, Kim L, Patton JT, Lapalombella R, Yu B, Wu Y, Roy S, De Leo A, Pileri S, Agostinelli C, Ayers L, Bradner JE, Chen-Kiang S, Elemento O, Motiwala T, Majumder S, Byrd JC, Jacob S, Sif S, Li C, Baiocchi RA.

Blood. 2015 Apr 16;125(16):2530-43. doi: 10.1182/blood-2014-12-619783. Epub 2015 Mar 5.

25.

The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.

Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA.

Cancer Immunol Res. 2015 Jul;3(7):787-94. doi: 10.1158/2326-6066.CIR-14-0242. Epub 2015 Mar 3.

26.

Human leukocyte antigen type and posttransplant lymphoproliferative disorder.

Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, Caligiuri MA, Baiocchi RA.

Transplantation. 2015 Jun;99(6):1220-5. doi: 10.1097/TP.0000000000000487.

PMID:
25427163
27.

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.

Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RA.

Oncotarget. 2015 Feb 20;6(5):2693-708.

28.

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM.

Leuk Lymphoma. 2015 Apr;56(4):1043-9. doi: 10.3109/10428194.2014.963073. Epub 2014 Nov 20.

29.

Driving toward targeted therapy for LCH.

Baiocchi RA.

Blood. 2014 Sep 4;124(10):1546-8. doi: 10.1182/blood-2014-07-587378. No abstract available.

30.

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.

Blachly JS, Baiocchi RA.

Br J Haematol. 2014 Oct;167(1):19-32. doi: 10.1111/bjh.13065. Epub 2014 Aug 6. Review.

PMID:
25100567
31.

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.

Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA.

Cancer. 2014 Jun 1;120(11):1677-85. doi: 10.1002/cncr.28642. Epub 2014 Feb 27.

32.

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA.

Cancer Res. 2014 Mar 15;74(6):1752-65. doi: 10.1158/0008-5472.CAN-13-0884. Epub 2014 Jan 22.

33.

Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.

Chung J, Karkhanis V, Tae S, Yan F, Smith P, Ayers LW, Agostinelli C, Pileri S, Denis GV, Baiocchi RA, Sif S.

J Biol Chem. 2013 Dec 6;288(49):35534-47. doi: 10.1074/jbc.M113.510669. Epub 2013 Nov 4.

34.

PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).

Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GB.

PLoS One. 2013 Sep 30;8(9):e74710. doi: 10.1371/journal.pone.0074710. eCollection 2013.

35.

Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.

Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas DM.

Clin Cancer Res. 2012 Sep 1;18(17):4600-11. doi: 10.1158/1078-0432.CCR-12-0839. Epub 2012 Jul 12.

36.

Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.

Alinari L, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RA.

Head Neck Pathol. 2012 Dec;6(4):496-501. doi: 10.1007/s12105-012-0378-z. Epub 2012 Jun 19.

37.
38.

Novel targeted therapies for mantle cell lymphoma.

Alinari L, Christian B, Baiocchi RA.

Oncotarget. 2012 Feb;3(2):203-11.

39.

Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues.

Tiwari R, Toppino A, Agarwal HK, Huo T, Byun Y, Gallucci J, Hasabelnaby S, Khalil A, Goudah A, Baiocchi RA, Darby MV, Barth RF, Tjarks W.

Inorg Chem. 2012 Jan 2;51(1):629-39. doi: 10.1021/ic202150b. Epub 2011 Dec 16.

40.

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA.

Blood. 2011 Dec 22;118(26):6893-903. doi: 10.1182/blood-2011-06-363879. Epub 2011 Oct 31.

41.

Versatility of PRMT5-induced methylation in growth control and development.

Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN, Sif S.

Trends Biochem Sci. 2011 Dec;36(12):633-41. doi: 10.1016/j.tibs.2011.09.001. Epub 2011 Oct 3. Review.

42.

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA.

Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14.

43.

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA.

Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.

44.

Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.

Prescott HC, Wu HM, Cataland SR, Baiocchi RA.

Am J Hematol. 2010 Dec;85(12):976-7. doi: 10.1002/ajh.21862. No abstract available.

45.

The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods.

Yan F, Wu X, Crawford M, Duan W, Wilding EE, Gao L, Nana-Sinkam SP, Villalona-Calero MA, Baiocchi RA, Otterson GA.

Methods. 2010 Dec;52(4):281-6. doi: 10.1016/j.ymeth.2010.09.005. Epub 2010 Oct 1.

46.

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen CS, Baiocchi RA, Byrd JC.

PLoS One. 2010 Jun 3;5(6):e10941. doi: 10.1371/journal.pone.0010941.

47.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA.

Blood. 2010 Sep 30;116(13):2286-94. doi: 10.1182/blood-2010-02-271874. Epub 2010 May 11.

48.

FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.

Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N.

Clin Cancer Res. 2010 Jun 15;16(12):3182-92. doi: 10.1158/1078-0432.CCR-09-2484. Epub 2010 May 11.

49.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G.

Cancer Cell. 2010 Apr 13;17(4):333-47. doi: 10.1016/j.ccr.2010.03.008.

50.

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA.

MAbs. 2009 Jan-Feb;1(1):31-40.

Supplemental Content

Loading ...
Support Center